Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate
Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate
About this item
Full title
Author / Creator
Publisher
Boston, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Hypophosphatemia, with associated changes in bone and mineral metabolism, developed in some patients with chronic myelogenous leukemia or gastrointestinal stromal tumors who were receiving imatinib, which inhibits several tyrosine kinases associated with these two diseases. The drug may thus inhibit bone remodeling in some patients.
Hypophosphat...
Alternative Titles
Full title
Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_19496965
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_19496965
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa051140
